Value creation for medical devices: lessons to be learnt from the pharmaceutical sector
This article was originally published in Clinica
Over the past few years the pharmaceutical industry has discovered a new talisman - the economic evaluation of medicines. Dr Neil Johnson looks at the achievements of the last few years and outlines the pitfalls that medical device and diagnostic companies should avoid as they become more and more involved in the field.
You may also be interested in...
Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.